Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1
The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis
What it found
Stopped early
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Revaxis
What it measured
Main measures
The primary endpoint will be measurement of the change in T-regulatory cells, by quantification of Foxp3 expression.
Who could take part
MS (type not specified)
Inclusion: Clinically definite multiple sclerosis Exclusion: Known allergy to any of the components of the vaccine Other history of allergy including seafood, hives, moderate to severe hayfever
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary endpoint will be measurement of the change in T-regulatory cells, by quantification of Foxp3 expression.
Loading reviews and guidelines…
History
Started
Mar 2010
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error